申联生物
(688098)
| 流通市值：34.29亿 | | | 总市值：34.29亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 111,920,730.05 | 62,598,409.64 | 288,266,467.14 | 237,694,760.86 |
| 营业总成本 | 126,866,313.85 | 60,149,695.32 | 306,578,474.55 | 235,297,261.25 |
| 其他经营收益 | | | | |
| 营业利润 | -23,908,132.78 | -2,820,669.94 | -27,857,850.63 | -2,611,073.2 |
| 利润总额 | -23,914,395.57 | -2,826,900.34 | -26,310,492.99 | -1,348,620.01 |
| 净利润 | -20,357,785.58 | -2,362,468.25 | -24,971,591.4 | -3,022,872 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -20,357,785.58 | -2,362,468.25 | -24,971,591.4 | -3,022,872 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 507,932,768.9 | 495,151,244.15 | 535,901,827.05 | 547,479,057.35 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,039,614,857.77 | 1,034,790,052.42 | 1,006,479,209.55 | 1,012,857,824.22 |
| 资产总计 | 1,547,547,626.67 | 1,529,941,296.57 | 1,542,381,036.6 | 1,560,336,881.57 |
| 流动负债: | | | | |
| 流动负债合计 | 143,445,194.43 | 123,845,448.36 | 133,328,214.2 | 128,125,771.64 |
| 非流动负债: | | | | |
| 非流动负债合计 | 8,913,552.87 | 9,487,334.49 | 10,081,840.43 | 11,291,408.56 |
| 负债合计 | 152,358,747.3 | 133,332,782.85 | 143,410,054.63 | 139,417,180.2 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,386,549,599.93 | 1,387,389,366.2 | 1,389,120,321.1 | 1,409,893,375.64 |
| 股东权益合计 | 1,395,188,879.37 | 1,396,608,513.72 | 1,398,970,981.97 | 1,420,919,701.37 |
| 负债和股东权益合计 | 1,547,547,626.67 | 1,529,941,296.57 | 1,542,381,036.6 | 1,560,336,881.57 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 82,849,756.74 | 45,113,657.09 | 278,942,649.79 | 159,813,427.48 |
| 经营活动现金流出小计 | 147,513,866.62 | 85,188,463.64 | 245,865,808.25 | 177,919,521.6 |
| 经营活动产生的现金流量净额 | -64,664,109.88 | -40,074,806.55 | 33,076,841.54 | -18,106,094.12 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 189,680,128.67 | 177,832,937.46 | 594,069,514.73 | 477,431,545.51 |
| 投资活动现金流出小计 | 208,143,781.56 | 177,516,789.54 | 643,233,904.97 | 493,779,805.21 |
| 投资活动产生的现金流量净额 | -18,463,652.89 | 316,147.92 | -49,164,390.24 | -16,348,259.7 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 56,198,348.02 | - | 16,317.38 | 16,317.38 |
| 筹资活动现金流出小计 | 988,551.54 | 161,203 | 3,522,577.06 | 2,770,862.95 |
| 筹资活动产生的现金流量净额 | 55,209,796.48 | -161,203 | -3,506,259.68 | -2,754,545.57 |
| 汇率变动对现金及现金等价物的影响 | -46 | -23.13 | -33.72 | -17.51 |
| 现金及现金等价物净增加额 | -27,918,012.29 | -39,919,884.76 | -19,593,842.1 | -37,208,916.9 |
| 期末现金及现金等价物余额 | 63,657,239.41 | 51,655,366.94 | 91,575,251.7 | 73,960,176.9 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -27,918,012.29 | - | -19,593,842.1 | - |